In the first week of July, Oxford will announce the effectiveness of the corona vaccine. The vaccine is currently in the final stages of trial. They will announce the final results within a week after the end of the third phase of the trial.
The third phase of the trial has began on last week in South Africa and Brazil with large-scale vaccinations of volunteers.
According to the international media, the vaccine will be administered to tens of thousands of volunteers in the final stage. Oxford also successfully completed the first and second round trials. Once approved at the end of the third trial, the pharmaceutical company AstraZeneca will start mass production.
AstraZeneca has already signed a contract with Oxford to produce the vaccine on a large scale without any profit. AstraZeneca aims to produce a total of 2 billion doses of the vaccine, including 400 million for the United States and the United Kingdom and 1 billion for low- and middle-income countries.
AstraZeneca CEO Pascal Sariot said, there are plans to start distributing the vaccine in the United States and the United Kingdom by September or October. We also plan to deliver the vaccine everywhere in early 2021.
AstraZeneca will distribute 400 million shots by 2020. It has entered into an agreement with the Serum Institute of India to supply 1 billion doses to low- and middle-income countries.
The vaccine, developed by Oxford, is called ENCOV-19 (ChAdOx1 nCoV-19) is under trial. Whether the vaccine is effective will be known soon. The UK government will approve it as soon as possible if it proves effective.
Sarah Gilbert, a Professor of Vaccineology at Oxford University, is leading the team. We are 70 percent confident of success, she said. Based on the tests, we can say that we have successfully developed the coronavirus vaccine.